Chardan raised the firm’s price target on Lexeo Therapeutics (LXEO) to $17 from $15 and keeps a Buy rating on the shares following the regulatory and data update for LX2006. The firm believes the FDA’s willingness to allow pooling of data from the ongoing Phase I/II studies support accelerated approval. Lexeo also shared updated data from the Phase I/II trials of LX2006, showing signals of sustained and dose-dependent improvements in left ventricular mass index, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXEO:
- IBM partners with Anthropic, Dell boosts long-term view: Morning Buzz
- Lexeo Therapeutics price target raised to $15 from $9 at H.C. Wainwright
- Positive Outlook for Lexeo Therapeutics: Regulatory Advancements and Promising LX2006 Data Boost Stock Target
- Lexeo Therapeutics price target raised to $20 from $9 at Leerink
- Morning Movers: IntercontinentalExchange up after $2B investment in Polymarket